SCHEMBL9907685

SCHEMBL9907685

Cc1ccc(-c2ncc(Cl)c3ccc(C(=O)O)cc23)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 4/20 0.47
PLAU P00749 3/20 0.42
PLG P00747 1/20 0.42
TNKS2 Q9H2K2 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.40
DHODH Q02127 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
RARA P10276 3/20 0.38
RARB P10826 3/20 0.38
RARG P13631 3/20 0.38
SLC22A12 Q96S37 1/20 0.38
MAPK1 P28482 1/20 0.38
MAP2K4 P45985 1/20 0.38
MAPKAPK3 Q16644 1/20 0.38
MAPK6 Q16659 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907769 0.89 HTR5A (0.57) HTR5APLAUPLGDHODH
SCHEMBL9907732 0.87 SRD5A2 (0.49) HTR5APLAUPLGMAP2K4KDM4E
SCHEMBL9907679 0.86 HTR5A (0.44) HTR5AMAPK1MAP2K4KDM4EALDH1A1
SCHEMBL9907688 0.85 HTR5A (0.60) HTR5APLAUPLGNAPRTMAPK1
SCHEMBL9909177 0.84 PLAU (0.47) HTR5APLAUPLGMRGPRX4KDM4E
SCHEMBL9907708 0.84 KDM4C (0.47) HTR5APLAUPLGTNKS2MRGPRX4
SCHEMBL9907941 0.83 HTR5A (0.69) HTR5APLAUPLG
SCHEMBL9907662 0.83 HTR5A (0.56) HTR5APLAUPLGDHODHNAPRT
SCHEMBL9907768 0.82 CSNK2A2 (0.52) HTR5APLAUPLGTNKS2DHODH
SCHEMBL9907678 0.81 HTR5A (0.57) HTR5APLAUPLGTNKS2MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E HTR5A 1/4885PLAU 3322/4885PLG 3328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.